8-K: Cryo-Cell Faces NYSE Delisting Threat Over Financial Woes

Cryo-Cell International received a notice from NYSE American indicating non-compliance with continued listing standards due to a stockholders deficit and recent net losses.

Summary

• Cryo-Cell International, Inc. (CCEL) received a notice from NYSE American LLC on March 9, 2026, stating non-compliance with continued listing standards under Section 1003(a).
• The non-compliance stems from reporting a stockholders deficit as of November 30, 2025, and net losses in two of its three most recent fiscal years (ended November 30, 2023, November 30, 2024, and November 30, 2025).
• The notice does not immediately affect the listing or trading of the company's common stock, which will continue to trade under the symbol CCEL.
• The company plans to submit a compliance plan to NYSE American by April 8, 2026.
• If the plan is accepted, the company may be granted up to 18 months to regain compliance.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development, as the company faces potential delisting due to fundamental financial weaknesses, despite having a plan to address it. The uncertainty of regaining compliance weighs heavily on future prospects.

Positives

• The company's common stock will continue to trade on the NYSE American under the symbol CCEL while it pursues a plan to regain compliance.
• The company has a history as the world's first private cord blood bank, founded in 1989, with over 500,000 parents from 87 countries entrusting their stem cells.
• Cryo-Cell operates a public banking program with Duke University and has provided cord blood for over 700 transplants.
• The facility is FDA registered, cGMP-/cGTP-compliant, licensed in all requiring states, AABB accredited, and was the first U.S. private cord blood bank to receive FACT accreditation.
• Holds exclusive rights to PrepaCyte-CB, an advanced cord blood processing technology.

Negatives

• Received a notice of non-compliance from NYSE American LLC regarding continued listing standards.
• Reported a stockholders deficit as of November 30, 2025.
• Incurred net losses in two of its three most recent fiscal years (ended November 30, 2023, November 30, 2024, and November 30, 2025).
• There is no assurance that NYSE American will accept the company's compliance plan or that the company will be able to regain compliance within any granted extension period.
• Failure to regain compliance could lead to delisting proceedings.

Risks

• Uncertainty regarding the acceptance of the compliance plan by NYSE American.
• Risk of not being able to regain compliance with NYSE American continued listing standards within any granted extension period.
• Potential delisting of common stock if compliance is not regained or other listing requirements are not met.
• Risks related to the success of global expansion initiatives and product diversification.
• Uncertainty regarding future ownership stake in therapies from collaborative research partnerships.
• Risks associated with the success of the company's intellectual property portfolio.
• Challenges related to the company's future competitive position in stem cell innovation.
• Impact of public cord blood banking on the company's core business.
• Uncertainty of profitability from biopharmaceutical manufacturing and operating clinics.
• Complexities, uncertainties, required consents, and timing related to the potential spinoff of Celle Corp.
• Ability to minimize future costs related to R&D initiatives and collaborations.
• Success and enforceability of umbilical cord blood and cord tissue license agreements and associated intellectual property.

Future Outlook

The company intends to submit a plan to regain compliance with NYSE American listing standards by April 8, 2026. If accepted, it may receive up to an 18-month extension to achieve compliance. However, there is no guarantee that the plan will be accepted or that compliance will be regained within any given timeframe.

Management Comments

• The Company intends to submit a plan of compliance to NYSE American by April 8, 2026, addressing how it intends to regain compliance with the continued listing standards.
• There can be no assurance that NYSE American will accept the Company's plan or that the Company will be able to regain compliance within any extension period that may be granted.

Industry Context

StockSavvy.ai notes that non-compliance with exchange listing standards, particularly due to financial metrics like stockholders deficit and recurring net losses, is a serious concern for publicly traded companies in the biotechnology and healthcare services sector. While Cryo-Cell has a strong historical position in cord blood banking, these financial indicators suggest underlying operational or market challenges that could impact its ability to invest in future growth or maintain investor confidence, contrasting with the capital-intensive nature of biotech R&D and expansion.

Comparison to Industry Standards

• The NYSE American's Section 1003(a) standards are fundamental for maintaining public listing, requiring companies to meet certain financial thresholds. Cryo-Cell's reported stockholders deficit and net losses in two of three recent fiscal years fall below these benchmarks, indicating a financial position weaker than typically expected for a stable, publicly traded company.
• Compared to industry leaders or well-capitalized peers in the biotech or specialized healthcare services sector, Cryo-Cell's current financial standing suggests a significant divergence from the robust balance sheets and consistent profitability often seen. For instance, companies like Thermo Fisher Scientific or Danaher, while much larger, consistently demonstrate strong financial health and growth, which allows for sustained R&D and market expansion. Even smaller, specialized biotech firms typically aim for a clear path to profitability or substantial capital reserves to fund operations, which appears challenged here.

Corporate Governance

Stakeholder Impact

• Shareholders: Face increased risk of stock delisting, potential loss of liquidity, and negative impact on share price due to financial instability and regulatory non-compliance.
• Employees: Potential uncertainty regarding the company's long-term stability if financial issues persist and delisting occurs.
• Customers (Parents): While the core service continues, persistent financial issues could raise concerns about the long-term viability and stability of their stored stem cells, though the company's accreditations provide some reassurance.
• Creditors: May face increased risk due to the stockholders deficit and ongoing net losses, potentially impacting the company's ability to meet its financial obligations.

Next Steps

• Cryo-Cell International, Inc. intends to submit a plan of compliance to NYSE American by April 8, 2026.
• If the plan is accepted, the company may be granted an extension of up to 18 months to regain compliance.
• The company is currently evaluating its options to regain compliance.

Key Dates

Recommendation

The notice of non-compliance from NYSE American, driven by a stockholders deficit and recurring net losses, signals significant financial distress and regulatory risk. While the company has a plan to address this, the uncertainty of acceptance and successful remediation within the timeframe, coupled with the potential for delisting, makes the stock a high-risk investment. A seasoned investor would likely view this as a strong indicator to exit positions to avoid further capital erosion and seek more financially stable opportunities.

Keywords

Cryo-Cell International, CCEL, NYSE American, Delisting Notice, Stockholders Deficit, Net Losses, Continued Listing Standards, Cord Blood Bank, Stem Cells, Financial Compliance, Biotechnology, Healthcare Services